Velocity Clinical Research has signed an exclusive research partnership with Coastal Heart Medical Group to transform specialty care by applying its integrated multi-site approach.

The alliance will focus on complex cardiovascular studies.

An integrated research site organisation, Velocity provides site expertise to aid biopharmaceutical and contract research organisation clients in finding the right patients for their studies. 

Velocity is applying its model to specialty care after establishing a network of over 30 integrated sites across the US that focuses on multitherapeutic primary care.

Standard enterprise-for-specialty-care models embed staff into current hospitals and academic facilities, without addressing operational issues that delay clinical trials and slow down the development of drugs. 

The site network of Velocity for specialised trials will have better technology standards and procedures for collecting data with the potential to scale rapidly.

Due to participant access and eligibility and procedural complications, specialty care studies face more challenges which cause stagnant enrolment and reduced diversity of patients. 

The organisation’s multi-site strategy for specialty care offers a solution for clinical trial sponsors to the enrolment challenges.

The collaboration between Velocity and Coastal Heart Medical intends to significantly boost clinical research opportunities available to all patients including people from minority populations by delivering trials to patient communities.

The first site of Velocity will be launched in Santa Ana, while the second one will be in Chino Hills, California to establish a network of specialty care sites in the US within two years. 

The focus of the first specialty care site will be on cardiology in progressive cases, interventional, surgical and devices procedures, all of which need to be carried out in special facilities.

The alliance offers a platform for interventional cardiology and vascular expertise, expanding the model across various specialty indications in the future.

Velocity Clinical Research Specialty Care senior vice-president Samira Moran said: “Velocity’s unique approach means we can scale our operations more efficiently to meet the demands of patients and the companies sponsoring this research. 

“We achieve greater diversity and inclusion by placing research at the heart of patient care in Hispanic and African American communities who need it the most.”

In February this year, the organisation made three investments in technology to extend patient community, enhance client engagement in trials and speed up the drug development in its 30 integrated locations.